



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
Rockville, MD 20857

NDA 50-733/S-023

Pfizer, Inc.  
Attention: Beatrice Curran  
Associate Director, Regulatory Affairs  
235 East 42<sup>nd</sup> Street, 685/18/16  
New York, NY 10017

Dear Ms. Curran:

Please refer to your supplemental new drug application NDA 50-733/S-023 dated February 6, 2009, received February 6, 2009 submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Zithromax (azithromycin) IV.

This supplemental new drug application provides for revisions to the **PRECAUTIONS -General and PRECAUTIONS-Drug Interactions** sections of the labeling.

We have completed the review of this application. This application is approved effective on the date of this letter, for use as recommended in the content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format submitted on February 6, 2009.

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format as described at <http://www.fda.gov/oc/datacouncil/spl.html> that is identical to the enclosed labeling submitted on February 6, 2009. Upon receipt, we will transmit this version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, "SPL for approved supplemental application NDA 21-821/S-016. Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH  
Food and Drug Administration  
Suite 12B05  
5600 Fishers Lane  
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Carmen DeBellas, Regulatory Project Manager, at (301) 796-1203.

Sincerely,

*{See appended electronic signature page}*

Sumathi Nambiar, MD, MPH  
Deputy Director for Safety  
Division of Anti-Infective and Ophthalmology Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

Enclosure:

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Sumathi Nambiar  
2/27/2009 02:18:06 PM